NASDAQ:DERM - Dermira Stock Price, Forecast & News

Dermira trades on the NASDAQ under the ticker symbol "DERM."

Dermira Inc (NASDAQ:DERM) issued its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.40) by $0.34. The biopharmaceutical company had revenue of $11.53 million for the quarter, compared to the consensus estimate of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%. View Dermira's Earnings History.

Dermira is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dermira.

8 brokers have issued 12 month price targets for Dermira's shares. Their forecasts range from $6.71 to $25.00. On average, they expect Dermira's stock price to reach $18.09 in the next twelve months. This suggests a possible upside of 129.6% from the stock's current price. View Analyst Price Targets for Dermira.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.

News articles about DERM stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dermira earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Dermira.

Dermira saw a increase in short interest in October. As of October 31st, there was short interest totalling 5,840,000 shares, an increase of 12.3% from the September 30th total of 5,200,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 5.3 days. Currently, 12.9% of the company's shares are short sold. View Dermira's Current Options Chain.

Some companies that are related to Dermira include Zymeworks (ZYME), Apellis Pharmaceuticals (APLS), Myovant Sciences (MYOV), Gossamer Bio (GOSS), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Alder Biopharmaceuticals (ALDR), Constellation Pharmaceuticals (CNST), Epizyme (EPZM), Corcept Therapeutics (CORT), Nabriva Therapeutics (NBRV), Esperion Therapeutics (ESPR), Athenex (ATNX), Axsome Therapeutics (AXSM) and Innoviva (INVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Celgene (CELG), Micron Technology (MU), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX) and TG Therapeutics (TGTX).

Dermira's stock is owned by a number of of retail and institutional investors. Top institutional investors include Great Point Partners LLC (4.81%), State Street Corp (1.73%), Rhenman & Partners Asset Management AB (1.01%), Millennium Management LLC (0.75%), Assenagon Asset Management S.A. (0.48%) and Squarepoint Ops LLC (0.33%). Company insiders that own Dermira stock include Christopher M Griffith, David E Cohen, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View Institutional Ownership Trends for Dermira.

DERM stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Assenagon Asset Management S.A. and First Midwest Bank Trust Division. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira.

DERM stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Rhenman & Partners Asset Management AB, Trellus Management Company LLC, State Street Corp, Squarepoint Ops LLC, Envestnet Asset Management Inc. and Virtu Financial LLC. View Insider Buying and Selling for Dermira.

Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DERM stock can currently be purchased for approximately $7.88.

Dermira has a market capitalization of $429.63 million and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe.View Additional Information About Dermira.

The official website for Dermira is http://www.dermira.com/.

Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]